Company / Depreciation & Amortization
Neurocrine Biosciences Depreciation & Amortization History
FY2016-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$4.0M
FY2018
5-year range
-
FY2016-FY2018
Trend
+67.7%
vs FY2017
Sector context
#80 of 162
Health Care
What the data says
At $4M, Neurocrine Biosciences's depreciation & amortization ranks #83 of 162 in the Health Care sector. Increased from $1M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2018.
Increased from $1M to $4M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#83 of 162 in Health CareTop 51% of 162This company $4.0M Sector average $220.5M
▼
-98.2% below sector average
Key checks
Key Insights
- In FY2018, depreciation & amortization increased 67.7% year-over-year.
- Ranks #80 out of 162 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $4.0M | +67.7% |
| FY2017 | $2.4M | +65.2% |
| FY2016 | $1.5M | +44.0% |
As of FY2018 · SEC 10-K · Updated Feb 28, 2026